In This Article:
BeiGene has climbed 32% over the past quarter, against a backdrop of significant industry challenges and broad market declines. The company's positive momentum can be attributed to the European Medicines Agency's positive opinion on TEVIMBRA, recommended for small cell lung cancer treatment, and its recent addition to the Hang Seng China Enterprises Index. These developments underscore BeiGene's expanding presence and potential in the competitive oncology market, providing a counter-narrative to the broader market, which suffered notable downturns due to tariff turmoil and escalating trade tensions between major global economies.
Buy, Hold or Sell BeiGene? View our complete analysis and fair value estimate and you decide.
Over the past year, BeiGene has experienced an impressive total shareholder return of 58.97%, significantly outperforming both the US Biotechs industry, which saw a 10.4% decline, and the broader US Market, which grew by 3.3%. A key driver of this strong performance was the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma in March 2025, followed by inclusion in the Hang Seng China Enterprises Index shortly after. These developments have strengthened BeiGene's market position and credibility.
Further bolstering the company's upward trajectory was its financial performance for the year ending December 2024, which saw a revenue increase to US$3.81 billion from US$2.46 billion the previous year, alongside a reduction in net losses. Additionally, the strategic collaboration announced with ImmunityBio, Inc. in January 2025 to conduct Phase 3 trials may position BeiGene for future pipeline advancements.
Evaluate BeiGene's prospects by accessing our earnings growth report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:ONC.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com